Aicardi Syndrome Market Research Report – Forecast to 2027

Aicardi Syndrome Research Report: by Diagnosis (Magnetic Resonance Imaging, Eye Examination, Others), by Treatment (Seizure Medication, Surgery, Physical Therapy, Others), by End User (Hospitals and Clinics, Diagnostic Centers)- Forecast Till 2027

ID: MRFR/Pharma/4922-HCR | | Region: Global | 100 pages

Aicardi Syndrome Market Scenario


Aicardi Syndrome market is expected to grow at a steady pace over the forecast period of 2018–2023. Aicardi syndrome is a rare genetic malformation syndrome characterized by the partial or complete absence of a key structure in the brain called the corpus callosum. The disorder primarily affects females, the mutation specifically occurs on the X chromosome. Symptoms of Aicardi syndrome include rib and spine abnormalities, such as scoliosis. Children with the syndrome may also have unusual facial features, such as larger ears, a flatter nose, or a smaller space between the upper lip and nose. Additionally, Aicardi syndrome can result in poorly developed eyes, impaired vision or blindness. The increasing research activities on rare disorders contribute to the growth of the market. For instance, Aicardi Syndrome Foundation, a non-profit organization contributes to ongoing research of Aicardi syndrome at Baylor University, Texas Children’s Hospital and The University of California, San Francisco.


The rising incidence of Aicardi syndrome, growing prevalence of rare disorders, technological advancements in the medical sector, and growing research and development (R&D) activities, are anticipated to drive the growth of the market during the forecast period.  Despite the driver, the lack of awareness about the syndrome in the developing regions and difficulties in diagnosis may restrain the growth of the Aicardi syndrome market over the forecast period.


Segmentation


The Aicardi syndrome market has been segmented into diagnosis, treatment, and end-user.


The market, based on diagnosis, has been segmented into magnetic resonance imaging (MRI), eye examination, and others.


The market, by treatment, has been segmented into seizure medication, surgery, physical therapy, occupational therapy, speech therapy, vision therapy, and others. The market, by seizure medication, is further segmented into vigabatrin, sodium valproate, and others.


The market, by end-user, has been segmented into hospital and clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Aicardi syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European Aicardi syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Aicardi syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Aicardi Syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Siemens Healthineers, General Electric Company, Koninklijke Philips N.V., Hitachi, Ltd., Canon Medical Systems Europe B.V., Medtronic, Smart Speech Therapy, Therapy Solutions Inc., Carestream Health, Esaote SpA, Lundbeck, and Novartis AG are some of the key players in the Aicardi syndrome market.


Regional Market Summary


Aicardi Syndrome Market Share (%), by Region, 2017


Aicardi Syndrome Market Share


Source: World Health Organization (WHO), Office for National Statistics, National Organization for Rare Disorders


Geographically, the Americas is anticipated to dominate the Aicardi Syndrome market owing to a rising research and development funding for rare diseases, and presence of well-developed healthcare infrastructure. Additionally, increasing healthcare expenditure provides a favorable background for pharmaceutical companies which is thereby expected to contribute to the market growth in the region. According to the Centers for Disease Control and Prevention (CDC), total national health expenditures were USD 3.2 trillion in 2015.


Europe is expected to hold the second largest position in the Aicardi syndrome market. The market growth in this region is attributed to the growing awareness of rare diseases and increasing research and development (R&D) activities. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing development in healthcare infrastructure, increasing number of regional expansions by multinational biopharmaceutical companies, and increasing government expenditure for the healthcare sector.


The Middle East & Africa is anticipated to account for the lowest market share in the Aicardi syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.


Market of Aicardi Syndrome, by Diagnosis



  • Magnetic Resonance Imaging (MRI)

  • Eye Examination

  • Others


Market of Aicardi Syndrome, by Treatment



  • Seizure Medication


    • Vigabatrin

    • Sodium Valproate

    • Others


  • Surgery

  • Physical Therapy

  • Occupational Therapy

  • Speech Therapy

  • Vision therapy

  • Others


Market of Aicardi Syndrome, by End-User



  • Hospital Clinics

  • Diagnostic Centers

  • Others


Market of Aicardi Syndrome, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • The Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Aicardi syndrome market would be affected by a lack of awareness among the populace.

The diagnostic segment of Aicardi syndrome market includes magnetic resonance imaging (MRI), eye examination, and others.

The treatment types of the Aicardi syndrome market report are vision therapy, surgery, seizure medication, occupational therapy, speech therapy, physical therapy, and others.

The end users discussed in the Aicardi syndrome market are diagnostic centers, hospitals & clinics, and others.

The Americas would ensure strong growth for the Aicardi syndrome market.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Aicardi Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Eye Examination

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Aicardi Syndrome Market, by Treatment

7.1 Introduction

7.2 Seizure Medication

7.2.1 Vigabatrin

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 Sodium Valproate

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Physical Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Occupational Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Speech Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.7 Vision therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.8 Others

Chapter 8. Global Aicardi Syndrome Market, by End-User

8.1 Hospital Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Aicardi Syndrome, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Siemens Healthineers

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 General Electric Company

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Koninklijke Philips N.V.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Hitachi, Ltd.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Canon Medical Systems Europe B.V.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Medtronic

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Smart Speech Therapy

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Therapy Solutions Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Carestream Health

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

1.9.5 SWOT Analysis

11.10 Esaote SpA

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Lundbeck

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Novartis AG

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Aicardi Syndrome Industry

Chapter 12. Appendix


LIST OF TABLES

Table 1 Global Aicardi Syndrome Market Synopsis, 2020–2027

Table 2 Global Aicardi Syndrome Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Aicardi Syndrome Market, by Region, 2020–2027(USD Million)

Table 4 Global Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 5 Global Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 6 Global Aicardi Syndrome Market, by End-user, 2020–2027(USD Million)

Table 7 North America: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 8 North America: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 9 North America: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 10 US: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 11 US: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 12 US: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 13 Canada: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 14 Canada: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 15 Canada: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million))

Table 16 South America: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 17 South America: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 18 South America: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 19 Europe: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 20 Europe: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 21 Europe: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 22 Western Europe: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 23 Western Europe: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 24 Western Europe: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 25 Eastern Europe: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 26 Eastern Europe: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 27 Eastern Europe: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 28 Asia-Pacific: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 29 Asia-Pacific: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 30 Asia-Pacific: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Aicardi Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

Table 32 Middle East & Africa: Aicardi Syndrome Market, by Treatment, 2020–2027 (USD Million)

Table 33 Middle East & Africa: Aicardi Syndrome Market, by End-User, 2020–2027 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Aicardi Syndrome Market

Figure 3 Segmentation Market Dynamics for Global Aicardi Syndrome Market

Figure 4 Global Aicardi Syndrome Market Share, by Diagnosis, 2020 (%)

Figure 5 Global Aicardi Syndrome Market Share, by Treatment, 2020 (%)

Figure 6 Global Aicardi Syndrome Market Share, by End-User, 2020 (%)

Figure 7 Global Aicardi Syndrome Market Share, by Region, 2020 (%)

Figure 8 North America: Aicardi Syndrome Market Share, by Country, 2020 (%)

Figure 9 Europe: Aicardi Syndrome Market Share, by Country, 2020 (%)

Figure 10 Asia-Pacific: Aicardi Syndrome Market Share, by Country, 2020 (%)

Figure 11 Middle East & Africa: Aicardi Syndrome Market Share, by Country, 2020 (%)

Figure 12 Global Aicardi Syndrome Market: Company Share Analysis, 2020 (%)

Figure 13 Siemens Healthineers: Key Financials

Figure 14 Siemens Healthineers: Segmental Revenue

Figure 15 Siemens Healthineers: Geographical Revenue

Figure 16 General Electric Company: Key Financials

Figure 17 General Electric Company: Segmental Revenue

Figure 18 General Electric Company: Geographical Revenue

Figure 19 Koninklijke Philips N.V.: Key Financials

Figure 20 Koninklijke Philips N.V.: Segmental Revenue

Figure 21 Koninklijke Philips N.V.: Geographical Revenue

Figure 22 Hitachi, Ltd.: Key Financials

Figure 23 Hitachi, Ltd.: Segmental Revenue

Figure 24 Hitachi, Ltd.: Geographical Revenue

Figure 25 Canon Medical Systems Europe B.V.: Key Financials

Figure 26 Canon Medical Systems Europe B.V.: Segmental Revenue

Figure 27 Canon Medical Systems Europe B.V.: Geographical Revenue

Figure 28 Medtronic: Key Financials

Figure 29 Medtronic: Segmental Revenue

Figure 30 Medtronic: Geographical Revenue

Figure 31 Smart Speech Therapy: Key Financials

Figure 32 Smart Speech Therapy: Segmental Revenue

Figure 33 Smart Speech Therapy: Geographical Revenue

Figure 34 Therapy Solutions Inc.: Key Financials

Figure 35 Therapy Solutions Inc.: Segmental Revenue

Figure 36 Therapy Solutions Inc.: Geographical Revenue

Figure 37 Carestream Health: Key Financials

Figure 38 Carestream Health: Segmental Revenue

Figure 39 Carestream Health: Geographical Revenue

Figure 40 Esaote SpA: Key Financials

Figure 41 Esaote SpA: Segmental Revenue

Figure 42 Esaote SpA: Geographical Revenue

Figure 43 Lundbeck: Key Financials

Figure 44 Lundbeck: Segmental Revenue

Figure 45 Lundbeck: Geographical Revenue

Figure 46 Novartis AG: Key Financials

Figure 47 Novartis AG: Segmental Revenue

Figure 48 Novartis AG: Geographical Revenue